- Home
- ASC vs TRDA Comparison
ASC vs TRDA Comparison
Compare ASC & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASC
- TRDA
- Stock Information
- Founded
- ASC 2010
- TRDA 2016
- Country
- ASC Bermuda
- TRDA United States
- Employees
- ASC N/A
- TRDA N/A
- Industry
- ASC Marine Transportation
- TRDA Biotechnology: Pharmaceutical Preparations
- Sector
- ASC Consumer Discretionary
- TRDA Health Care
- Exchange
- ASC Nasdaq
- TRDA Nasdaq
- Market Cap
- ASC 382.7M
- TRDA 336.6M
- IPO Year
- ASC 2013
- TRDA 2021
- Fundamental
- Price
- ASC $9.91
- TRDA $8.38
- Analyst Decision
- ASC Buy
- TRDA Strong Buy
- Analyst Count
- ASC 3
- TRDA 3
- Target Price
- ASC $13.67
- TRDA $25.67
- AVG Volume (30 Days)
- ASC 464.6K
- TRDA 139.5K
- Earning Date
- ASC 05-07-2025
- TRDA 05-08-2025
- Dividend Yield
- ASC 6.94%
- TRDA N/A
- EPS Growth
- ASC N/A
- TRDA N/A
- EPS
- ASC 2.30
- TRDA 0.61
- Revenue
- ASC $373,479,000.00
- TRDA $172,220,000.00
- Revenue This Year
- ASC N/A
- TRDA N/A
- Revenue Next Year
- ASC N/A
- TRDA N/A
- P/E Ratio
- ASC $4.21
- TRDA $14.69
- Revenue Growth
- ASC N/A
- TRDA 5.74
- 52 Week Low
- ASC $8.32
- TRDA $7.10
- 52 Week High
- ASC $23.44
- TRDA $21.79
- Technical
- Relative Strength Index (RSI)
- ASC 56.51
- TRDA 43.04
- Support Level
- ASC $9.41
- TRDA $7.71
- Resistance Level
- ASC $10.26
- TRDA $9.46
- Average True Range (ATR)
- ASC 0.32
- TRDA 0.60
- MACD
- ASC 0.08
- TRDA 0.05
- Stochastic Oscillator
- ASC 74.45
- TRDA 38.29
About ASC Ardmore Shipping Corporation
Ardmore Shipping Corp provides seaborne transportation of petroleum products and chemicals world-wide to oil majors, national oil companies, oil and chemical traders, and chemical companies, with its modern, fuel-efficient fleet of mid-size product and chemical tankers. The Company operates its business in one operating segment, the transportation of refined petroleum products and chemicals.
About TRDA Entrada Therapeutics Inc.
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.